R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J. Clin, vol.69, pp.7-34, 2019.

B. Ljungberg, S. C. Campbell, H. Y. Choi, D. Jacqmin, J. E. Lee et al., The epidemiology of renal cell carcinoma, Eur. Urol, vol.60, pp.615-621, 2011.

L. Gossage, T. Eisen, and E. R. Maher, Vhl, the story of a tumour suppressor gene, Nat. Rev. Cancer, vol.15, pp.55-64, 2015.

H. Akaza and T. Fukuyama, Axitinib for the treatment of advanced renal cell carcinoma, Expert Opin. Pharmacother, vol.15, pp.283-297, 2014.

R. J. Motzer, T. E. Hutson, D. Cella, J. Reeves, R. Hawkins et al., Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med, vol.369, pp.722-731, 2013.

T. K. Choueiri, B. Escudier, T. Powles, P. N. Mainwaring, B. I. Rini et al., Cabozantinib versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med, vol.373, pp.1814-1823, 2015.

B. I. Rini, S. K. Pal, B. J. Escudier, M. B. Atkins, T. E. Hutson et al., Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (tivo-3): A phase 3, multicentre, randomised, controlled, open-label study, Lancet Oncol, vol.21, pp.95-104, 2020.

H. Moch, A. L. Cubilla, P. A. Humphrey, V. E. Reuter, and T. M. Ulbright, The 2016 who classification of tumours of the urinary system and male genital organs-part a: Renal, penile, and testicular tumours, Eur. Urol, vol.70, pp.93-105, 2016.

. Cancer-genome-atlas, N. Research, W. M. Linehan, P. T. Spellman, C. J. Ricketts et al., Comprehensive molecular characterization of papillary renal-cell carcinoma, N. Engl. J. Med, vol.374, pp.135-145, 2016.

P. Argani, Mit family translocation renal cell carcinoma, Semin. Diagn. Pathol, vol.32, pp.103-113, 2015.

G. G. Malouf, F. A. Monzon, J. Couturier, V. Molinie, B. Escudier et al., Genomic heterogeneity of translocation renal cell carcinoma, Clin. Cancer Res, vol.19, pp.4673-4684, 2013.

G. G. Malouf, E. Comperat, H. Yao, R. Mouawad, V. Lindner et al., Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas, Sci. Rep, vol.6, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01357776

M. I. Carlo, J. Chaim, S. Patil, Y. Kemel, A. M. Schram et al., Genomic characterization of renal medullary carcinoma and treatment outcomes, Clin. Genitourin. Cancer, vol.15, pp.987-994, 2017.

Y. B. Chen, A. R. Brannon, A. Toubaji, M. E. Dudas, H. H. Won et al., Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: Recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry, Am. J. Surg. Pathol, vol.38, pp.627-637, 2014.

G. G. Malouf, S. M. Ali, K. Wang, S. Balasubramanian, J. S. Ross et al., Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations, Eur. Urol, vol.70, pp.348-357, 2016.

L. Albiges, T. Powles, M. Staehler, K. Bensalah, R. H. Giles et al., Updated european association of urology guidelines on renal cell carcinoma: Immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma, Eur. Urol, vol.76, pp.151-156, 2019.

R. J. Motzer, J. Bacik, B. A. Murphy, P. Russo, and M. Mazumdar, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J. Clin. Oncol, vol.20, pp.289-296, 2002.

G. Fyfe, R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson et al., Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy, J. Clin. Oncol, vol.13, pp.688-696, 1995.

, Int. J. Mol. Sci, 2020.

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med, vol.356, pp.115-124, 2007.

R. J. Motzer, N. M. Tannir, D. F. Mcdermott, O. .;-aren-frontera, B. Melichar et al., Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N. Engl. J. Med, vol.378, pp.1277-1290, 2018.

R. J. Motzer, B. Escudier, D. F. Mcdermott, S. George, H. J. Hammers et al., Nivolumab versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med, vol.373, pp.1803-1813, 2015.

K. R. Leite, S. T. Reis, J. P. Junior, M. Zerati, O. Gomes-dde et al., Pd-l1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis, Diagn. Pathol, vol.10, 2015.

R. H. Thompson, H. Dong, and E. D. Kwon, Implications of b7-h1 expression in clear cell carcinoma of the kidney for prognostication and therapy, Clin. Cancer Res, vol.13, pp.709-715, 2007.

R. H. Thompson, H. Dong, C. M. Lohse, B. C. Leibovich, M. L. Blute et al., Pd-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma, Clin. Cancer Res, vol.13, pp.1757-1761, 2007.

R. J. Motzer, K. Penkov, J. Haanen, B. Rini, L. Albiges et al., Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med, vol.380, pp.1103-1115, 2019.

B. I. Rini, E. R. Plimack, V. Stus, R. Gafanov, R. Hawkins et al., Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N. Engl. J. Med, vol.380, pp.1116-1127, 2019.

P. Sharma, S. Hu-lieskovan, J. A. Wargo, and A. Ribas, Primary, adaptive, and acquired resistance to cancer immunotherapy, vol.168, pp.707-723, 2017.

G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, Cancer immunoediting: From immunosurveillance to tumor escape, Nat. Immunol, vol.3, pp.991-998, 2002.

A. C. Anderson, N. Joller, and V. K. Kuchroo, Lag-3, tim-3, and tigit: Co-inhibitory receptors with specialized functions in immune regulation, Immunity, vol.44, pp.989-1004, 2016.

D. Lambrechts, E. Wauters, B. Boeckx, S. Aibar, D. Nittner et al., Phenotype molding of stromal cells in the lung tumor microenvironment, Nat. Med, vol.24, pp.1277-1289, 2018.

T. Akino, K. Hida, Y. Hida, K. Tsuchiya, D. Freedman et al., Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors, Am. J. Pathol, vol.175, pp.2657-2667, 2009.

J. Edeline, S. Mottier, C. Vigneau, F. Jouan, C. Perrin et al., Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma, Hum. Pathol, vol.43, 1982.
URL : https://hal.archives-ouvertes.fr/inserm-00702346

M. Dufies, S. Giuliano, D. Ambrosetti, A. Claren, P. D. Ndiaye et al., Sunitinib stimulates expression of vegfc by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas, Cancer Res, vol.77, pp.1212-1226, 2017.

R. H. Thompson, S. M. Kuntz, B. C. Leibovich, H. Dong, C. M. Lohse et al., Tumor b7-h1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up, Cancer Res, vol.66, pp.3381-3385, 2006.

T. K. Choueiri, A. P. Fay, K. P. Gray, M. Callea, T. H. Ho et al., Pd-l1 expression in nonclear-cell renal cell carcinoma, Ann. Oncol, vol.25, pp.2178-2184, 2014.

S. Gupta, J. C. Cheville, A. A. Jungbluth, Y. Zhang, L. Zhang et al., 1) amplifications in renal cell carcinomas with sarcomatoid transformation: Implications for clinical management, Mod. Pathol, vol.32, pp.1344-1358, 2019.

S. Chevrier, J. H. Levine, V. R. Zanotelli, K. Silina, D. Schulz et al., An immune atlas of clear cell renal cell carcinoma, vol.169, pp.736-749, 2017.

N. A. Giraldo, E. Becht, Y. Vano, F. Petitprez, L. Lacroix et al., Tumor-infiltrating and peripheral blood t-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma, Clin. Cancer Res, vol.23, pp.4416-4428, 2017.

E. Sjoberg, M. Frodin, J. Lovrot, A. Mezheyeuski, M. Johansson et al., A minority-group of renal cell cancer patients with high infiltration of cd20 + b-cells is associated with poor prognosis, Br. J. Cancer, vol.119, pp.840-846, 2018.

T. K. Choueiri, M. N. Fishman, B. Escudier, D. F. Mcdermott, C. G. Drake et al., Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma, Clin. Cancer Res, vol.22, pp.5461-5471, 2016.

S. Shirotake, G. Kaneko, K. Nagata, M. Oyama, and K. Nishimoto, Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report, Mol. Clin. Oncol, vol.10, pp.244-248, 2019.

B. I. Rini, T. Powles, M. B. Atkins, B. Escudier, D. F. Mcdermott et al., Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (immotion151): A multicentre, open-label, phase 3, randomised controlled trial, Lancet, vol.393, pp.2404-2415, 2019.

R. J. Motzer, B. I. Rini, D. F. Mcdermott, O. .;-aren-frontera, H. J. Hammers et al., Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, Lancet Oncol, vol.20, pp.1370-1385, 2019.

A. A. Lalani, B. A. Mcgregor, L. Albiges, T. K. Choueiri, R. Motzer et al., Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions, Eur. Urol, vol.75, pp.100-110, 2019.

Y. Tomita, S. Fukasawa, N. Shinohara, H. Kitamura, M. Oya et al., Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the checkmate 025 study, Jpn. J. Clin. Oncol, vol.47, pp.639-646, 2017.

A. Ravaud, R. J. Motzer, H. S. Pandha, D. J. George, A. J. Pantuck et al., Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy, N. Engl. J. Med, vol.375, pp.2246-2254, 2016.

R. J. Motzer, E. Jonasch, M. D. Michaelson, L. Nandagopal, J. L. Gore et al., Nccn guidelines insights: Kidney cancer, version 2.2020, J. Natl. Compr. Cancer Netw, vol.17, pp.1278-1285, 2019.

F. E. Vera-badillo, A. J. Templeton, I. Duran, A. Ocana, P. De-gouveia et al., Systemic therapy for non-clear cell renal cell carcinomas: A systematic review and meta-analysis, Eur. Urol, vol.67, pp.740-749, 2015.

V. S. Koshkin, P. C. Barata, T. Zhang, D. J. George, M. B. Atkins et al., Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma, J. Immunother. Cancer, vol.6, issue.9, 2018.

J. L. Benci, B. Xu, Y. Qiu, T. J. Wu, H. Dada et al., Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade, Cell, vol.167, pp.1540-1554, 2016.

X. Gao, Y. Zhu, G. Li, H. Huang, G. Zhang et al., Tim-3 expression characterizes regulatory t cells in tumor tissues and is associated with lung cancer progression, PLoS ONE, vol.7, 2012.

K. Sakuishi, L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo et al., Targeting tim-3 and pd-1 pathways to reverse t cell exhaustion and restore anti-tumor immunity, J. Exp. Med, vol.207, pp.2187-2194, 2010.

J. G. Casado, G. Pawelec, S. Morgado, B. Sanchez-correa, E. Delgado et al., Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines, Cancer Immunol. Immunother, vol.58, pp.1517-1526, 2009.

, Int. J. Mol. Sci, 2020.

K. Inamura, G. Amori, T. Yuasa, S. Yamamoto, J. Yonese et al., Relationship of b7-h3 expression in tumor cells and tumor vasculature with foxp3+ regulatory t cells in renal cell carcinoma, Cancer Manag. Res, vol.11, pp.7021-7030, 2019.

L. Wang, R. Rubinstein, J. L. Lines, A. Wasiuk, C. Ahonen et al., Vista, a novel mouse ig superfamily ligand that negatively regulates t cell responses, J. Exp. Med, vol.208, pp.577-592, 2011.

L. Mercier, I. Chen, W. Lines, J. L. Day, M. Li et al., Vista regulates the development of protective antitumor immunity, Cancer Res, vol.74, pp.1933-1944, 2014.

C. Fos, A. Salles, V. Lang, F. Carrette, S. Audebert et al., Icos ligation recruits the p50alpha pi3k regulatory subunit to the immunological synapse, J. Immunol, vol.181, pp.1969-1977, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00282605

S. Aspeslagh, S. Postel-vinay, S. Rusakiewicz, J. C. Soria, L. Zitvogel et al., Rationale for anti-ox40 cancer immunotherapy, Eur. J. Cancer, vol.52, pp.50-66, 2016.

E. M. Shevach and G. L. Stephens, The gitr-gitrl interaction: Co-stimulation or contrasuppression of regulatory activity?, Nat. Rev. Immunol, vol.6, pp.613-618, 2006.

R. Ramapriyan, M. S. Caetano, H. B. Barsoumian, A. C. Mafra, E. P. Zambalde et al., Altered cancer metabolism in mechanisms of immunotherapy resistance, Pharmacol. Ther, vol.195, pp.162-171, 2019.

J. Y. Chen, C. F. Li, C. C. Kuo, K. K. Tsai, M. F. Hou et al., Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression, Breast Cancer Res, vol.16, p.410, 2014.

J. E. Cheong and L. Sun, Targeting the ido1/tdo2-kyn-ahr pathway for cancer immunotherapy-challenges and opportunities, Trends Pharmacol. Sci, vol.39, pp.307-325, 2018.

R. D. Leone and L. A. Emens, Targeting adenosine for cancer immunotherapy, J. Immunother. Cancer, vol.6, 2018.

C. Linnemann, F. A. Schildberg, A. Schurich, L. Diehl, S. I. Hegenbarth et al., Adenosine regulates cd8 t-cell priming by inhibition of membrane-proximal t-cell receptor signalling, Immunology, vol.128, pp.728-737, 2009.

E. Ananieva, Targeting amino acid metabolism in cancer growth and anti-tumor immune response, World J. Biol. Chem, vol.6, pp.281-289, 2015.

M. A. Dawson and T. Kouzarides, Cancer epigenetics: From mechanism to therapy, Cell, vol.150, pp.12-27, 2012.

T. Eckschlager, J. Plch, M. Stiborova, and J. Hrabeta, Histone deacetylase inhibitors as anticancer drugs, Int. J. Mol. Sci, vol.18, 2017.

R. Y. Pan, W. H. Chung, M. T. Chu, S. J. Chen, H. C. Chen et al., Recent development and clinical application of cancer vaccine: Targeting neoantigens, J. Immunol. Res, 2018.

H. Li, J. Ding, M. Lu, H. Liu, Y. Miao et al., Caix-specific car-t cells and sunitinib show synergistic effects against metastatic renal cancer models, J. Immunother, vol.43, pp.16-28, 2020.

D. Y. Heng, W. Xie, M. M. Regan, L. C. Harshman, G. A. Bjarnason et al., External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: A population-based study, Lancet Oncol, vol.14, pp.141-148, 2013.

N. Kroeger, T. Klatte, K. Chamie, P. N. Rao, F. D. Birkhauser et al., Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma, Cancer, vol.119, pp.1547-1554, 2013.

S. F. Kammerer-jacquet, A. Deleuze, J. Saout, R. Mathieu, B. Laguerre et al., Targeting the pd-1/pd-l1 pathway in renal cell carcinoma, Int. J. Mol. Sci, 1692.
URL : https://hal.archives-ouvertes.fr/hal-02119178

A. Seeber, G. Klinglmair, J. Fritz, F. Steinkohl, K. C. Zimmer et al., High ido-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma, Cancer Sci, vol.109, pp.1583-1591, 2018.

, Int. J. Mol. Sci, 2020.

B. Beuselinck, S. Job, E. Becht, A. Karadimou, V. Verkarre et al., Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting, Clin. Cancer Res, vol.21, pp.1329-1339, 2015.

A. A. Hakimi, M. H. Voss, F. Kuo, A. Sanchez, M. Liu et al., Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer-data from a randomized phase iii trial, Cancer Discov, vol.9, pp.510-525, 2019.

D. F. Mcdermott, M. A. Huseni, M. B. Atkins, R. J. Motzer, B. I. Rini et al., Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat. Med, vol.24, pp.749-757, 2018.

R. W. Joseph, S. Z. Millis, E. M. Carballido, D. Bryant, Z. Gatalica et al., Pd-1 and pd-l1 expression in renal cell carcinoma with sarcomatoid differentiation, Cancer Immunol. Res, vol.3, pp.1303-1307, 2015.

A. Kamoun, A. De-reynies, Y. Allory, G. Sjodahl, A. G. Robertson et al., A consensus molecular classification of muscle-invasive bladder cancer, Eur. Urol, vol.77, pp.420-433, 2019.

Z. R. Chalmers, C. F. Connelly, D. Fabrizio, L. Gay, S. M. Ali et al., Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.9, 2017.

G. De-velasco, D. Miao, M. H. Voss, A. A. Hakimi, J. J. Hsieh et al., Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups, Cancer Immunol. Res, vol.4, pp.820-822, 2016.

D. Miao, C. A. Margolis, W. Gao, M. H. Voss, W. Li et al., Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma, Science, vol.359, pp.801-806, 2018.

J. C. Dudley, M. T. Lin, D. T. Le, and J. R. Eshleman, Microsatellite instability as a biomarker for pd-1 blockade, Clin. Cancer Res, vol.22, pp.813-820, 2016.

L. Derosa, M. D. Hellmann, M. Spaziano, D. Halpenny, M. Fidelle et al., Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer, Ann. Oncol, vol.29, pp.1437-1444, 2018.

E. Becht, N. A. Giraldo, L. Lacroix, B. Buttard, N. Elarouci et al., Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression, Genome Biol, vol.17, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01398093

M. Gerlinger, J. W. Catto, T. F. Orntoft, F. X. Real, E. C. Zwarthoff et al., Intratumour heterogeneity in urologic cancers: From molecular evidence to clinical implications, Eur. Urol, vol.67, pp.729-737, 2015.

M. L. Suva and I. Tirosh, Single-cell rna sequencing in cancer: Lessons learned and emerging challenges, Mol. Cell, vol.75, pp.7-12, 2019.

K. T. Kim, H. W. Lee, H. O. Lee, H. J. Song, E. Jeong-da et al., Application of single-cell rna sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma, Genome Biol, vol.17, 2016.

C. Roelants, C. Pillet, Q. Franquet, C. Sarrazin, N. Peilleron et al., Ex-vivo treatment of tumor tissue slices as a predictive preclinical method to evaluate targeted therapies for patients with renal carcinoma, Cancers
URL : https://hal.archives-ouvertes.fr/inserm-02465631

T. G. Meijer, K. A. Naipal, A. Jager, and D. C. Van-gent, Ex vivo tumor culture systems for functional drug testing and therapy response prediction, Future Sci

Y. D. Seo, X. Jiang, K. M. Sullivan, F. G. Jalikis, K. S. Smythe et al., Mobilization of cd8( + ) t cells via cxcr4 blockade facilitates pd-1 checkpoint therapy in human pancreatic cancer, Clin. Cancer Res, vol.25, pp.3934-3945, 2019.

K. K. Dijkstra, C. M. Cattaneo, F. Weeber, M. Chalabi, J. Van-de-haar et al., Generation of tumor-reactive t cells by co-culture of peripheral blood lymphocytes and tumor organoids, Cell, vol.174, pp.1586-1598, 2018.

, Int. J. Mol. Sci, 2020.

F. Bensch, E. L. Van-der-veen, M. N. Lub-de-hooge, A. Jorritsma-smit, R. Boellaard et al., )zr-atezolizumab imaging as a non-invasive approach to assess clinical response to pd-l1 blockade in cancer, Nat. Med, vol.24, issue.89, pp.1852-1858, 2018.

R. Sun, E. J. Limkin, M. Vakalopoulou, L. Dercle, S. Champiat et al., A radiomics approach to assess tumour-infiltrating cd8 cells and response to anti-pd-1 or anti-pd-l1 immunotherapy: An imaging biomarker, retrospective multicohort study, Lancet Oncol, vol.19, pp.1180-1191, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01958243

A. Gradilone, R. Iacovelli, E. Cortesi, C. Raimondi, W. Gianni et al., Circulating tumor cells and "suspicious objects" evaluated through cellsearch(r) in metastatic renal cell carcinoma, Anticancer. Res, vol.31, pp.4219-4221, 2011.

H. He and C. Magi-galluzzi, Epithelial-to-mesenchymal transition in renal neoplasms, Adv. Anat. Pathol, vol.21, pp.174-180, 2014.

S. Liu, Z. Tian, L. Zhang, S. Hou, S. Hu et al., Combined cell surface carbonic anhydrase 9 and cd147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients, Oncotarget, vol.7, pp.59877-59891, 2016.

M. Santoni, A. Cimadamore, L. Cheng, A. Lopez-beltran, N. Battelli et al., Circulating tumor cells in renal cell carcinoma: Recent findings and future challenges, Front. Oncol, vol.9, p.228, 2019.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI